BusinessBeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia PreventionBy Nasdaq OMXApr 25, 2017, 12:32 PM UTC
BusinessBeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia PreventionBy Nasdaq OMXApr 25, 2017, 12:32 PM UTC
BusinessTaconic Biosciences Launches ExpressMODEL™, a New Accelerated Model Generation ServiceBy Nasdaq OMXApr 3, 2017, 2:30 PM UTC
BusinessBeyondSpring Chief Medical Offer to Present on Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Prevention at BIO-Europe Spring 2017By Nasdaq OMXMar 22, 2017, 12:30 PM UTC
BusinessBeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British ColumbiaBy Nasdaq OMXMar 20, 2017, 12:30 PM UTC
BusinessBeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in TokyoBy Nasdaq OMXMar 14, 2017, 12:31 PM UTC
BusinessBeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in TokyoBy Nasdaq OMXMar 14, 2017, 12:31 PM UTC
BusinessCascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial ResultsBy Nasdaq OMXMar 9, 2017, 9:02 PM UTC
